Statement of Changes in Beneficial Ownership (4)

New Post Public Reply Private Reply Replies (0) Message Board
CyberC
316

Statement of Changes in Beneficial Ownership (4)
Print
Alert
FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *
Mann Michael Scott 2. Issuer Name and Ticker or Trading Symbol
ENDONOVO THERAPEUTICS, INC. [ ENDV ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director __ X __ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
President
(Last) (First) (Middle)
6320 CANOGA AVENUE 3. Date of Earliest Transaction (MM/DD/YYYY)
7/25/2017
(Street)
WOODLAND HILLS, CA 91367
(City) (State) (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 7/25/2017 P 5000 A $0.0298 22009389 D
Common Stock 7/25/2017 P 3000 A $0.0392 22012389 D
Common Stock 7/25/2017 P 2000 A $0.039 22014389 D
Common Stock 7/25/2017 P 2000 A $0.039 22016389 D
Common Stock 7/25/2017 P 3500 A $0.0386 22019889 D
Common Stock 7/25/2017 P 3500 A $0.0372 22023389 D
Common Stock 7/25/2017 P 2000 A $0.0376 22025389 D
Common Stock 7/26/2017 P 3000 A $0.035 22028389 D
Common Stock 7/26/2017 P 3000 A $0.0385 22031389 D

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Mann Michael Scott
6320 CANOGA AVENUE
WOODLAND HILLS, CA 91367
X President

Signatures
Michael Mann 7/27/2017
** Signature of Reporting Person Date

Endonovo Therapeutics, Inc. (ENDV) Stock Research Links

ENDV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Protecting Shareholder Rights: iRhythm Technologies Update

Updated Category News Views 104

Understanding Your Rights as a Shareholder For shareholders of iRhythm Technologies, Inc. (NASDAQ: IRTC), it's imperative to be proactive regarding your rights. Engaging with legal experts can significantly empower your ability to affect change and seek justice for any personal or collective grievances stemming from corporate actions. Why Shareholder Action is Crucial...

Continue Reading
Discover the New Credit Risk IQ and its Industry Insights

Updated Category News Views 138

Introducing Credit Risk IQ Credit Benchmark, a leader in delivering essential credit risk data and analytics, has launched an exciting new platform called Credit Risk IQ. This online portal features an extensive library of over 5,000 free monthly reports that explore credit trends at both industry and sector levels. The insights found in these reports are invaluable for...

Continue Reading
9Rooftops Retained as Marketing Agency for South Carolina Tourism

Updated Category News Views 233

9Rooftops Reappointed for South Carolina Tourism Marketing 9Rooftops, known for its innovative marketing strategies, has been reappointed as the Marketing and Advertising Agency of Record for the South Carolina Department of Parks, Recreation & Tourism (SCPRT). This marks a continued partnership aimed at showcasing the beauty and attractions of South Carolina. A...

Continue Reading
Kyivstar Enhances Digital Services with AI Cloud Solutions

Updated Category News Views 203

Kyivstar Revolutionizes Cloud Services with AI Integration Kyivstar Group Ltd (Nasdaq: KYIV; KYIVW) has embarked on an ambitious journey to strengthen digital services within Ukraine. The company has officially announced the integration of groundbreaking artificial intelligence (AI) technologies into its cloud platform, Kyivstar Cloud. This advancement is pivotal for all...

Continue Reading
Akeso Advances Cancer Care with Ivonescimab Phase III Trial Launch

Updated Category News Views 171

Akeso Launches Phase III Trial for Ivonescimab in SCLC Akeso, Inc. (9926.HK) recently announced an exciting milestone in cancer treatment with the first patient being dosed in its Phase III clinical trial. This multicenter, randomized, and double-blind study, named AK112-311/HARMONi-9, evaluates the efficacy and safety of ivonescimab, a unique bispecific antibody that...

Continue Reading